Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2016-001878-15-Outside-EU/EEA
EUCTR2016-001878-15-Outside-EU/EEAActive, not recruitingPhase 1

Single and Multiple Dose Pharmacokinetics and Safety Study of Rabeprazole Sodium in 12 to 16 Year Old Subjects

Eisai Medical Research Inc.0 sites24 target enrollmentStarted: June 27, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
24
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Males and females age 12 to 16 years, with a clinical diagnosis of, or symptoms of, GERD.
  • •2. Subjects had to be able and willing to take the required number of test drug tablets.
  • •3. The ability of the child to swallow an intact tablet had to be confirmed by the site at screening by history taking.
  • •4. Minimum weight of 30 kg.
  • •5. Willingness of the subject and ability to give assent to participate.
  • •6. The subject's parent or guardian provided written informed consent.
  • •7. Post-pubertal females were required to abstain from sexual relations during the course of the study.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 24
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric or cardiovascular system abnormalities, unless the Sponsor and Investigator agreed that the nature and severity of any abnormality was unlikely to interfere with the conduct of the study, the interpretation of study results, or the health of the subject during the study.
  • •2. Females who were pregnant, lactating or had a positive urine beta-human chorionic gonadotropin (hCG) laboratory result.
  • •3. Subjects who were unwilling or unable to refrain from smoking or drinking alcohol starting from 48 hours prior to screening and dosing, through the end of the study, and/or a positive urine drug screen.
  • •4. Subjects who were unwilling or unable to abide by the requirements of the study or who violated the prohibitions and restrictions of the study defined in the Study Protocol.
  • •5. Any condition, which in the opinion of the Investigator or Sponsor, would make the subject unsuitable for the study.
  • •6. Participation in another investigational drug study within 30 days prior to drug administration.
  • •7. A subject history of drug allergies or sensitivity to proton pump inhibitors or to their inactive ingredients.
  • •8. A subject history of clinically significant bacterial or viral infection within one month of screening.
  • •9. Subject history of definitive acid-lowering surgery or previous esophageal or gastric surgery, with the exception of a simple closure of a perforated ulcer.

Investigators

Similar Trials

Active, not recruiting
Phase 1
A research project to find out how safe and effective a single dose of TAK-491 research medicine is, after it has been taken by children aged 6 months – 16 years who have high blood pressure. Healthy adults will also be included in this research project to provide a comparison.Hypertension
EUCTR2009-013165-25-GBTakeda Development Centre Europe Ltd.29
Active, not recruiting
Not Applicable
A research project to find out how safe and effective a single dose of TAK-491 research medicine is, after it has been taken by children aged 6 months – 16 years who have high blood pressure. Healthy adults will also be included in this research project to provide a comparison.MedDRA version: 14.1Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 14.1Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersHypertension
EUCTR2009-013165-25-Outside-EU/EEATakeda Global Research & Development Centre (Europe) Ltd.32
Active, not recruiting
Not Applicable
The pharmacokinetics of single and multiple doses of intravenous paracetamol in children - Pharmacokinetics of I.V paracetamol in childreThere is no medical condition to be investigated. This is a pharmacokinetic study to be performed in children routinely treated with intravenous paracetamol for post surgical pain in line with local treatment protocol.
EUCTR2009-012585-30-GBHS Grampian Research and Development
Active, not recruiting
Not Applicable
The pharmacokinetics of single and multiple doses of intravenous ketorolac in children - Pharmacokinetics of I.V Ketorolac in ChildreThere is no medical condition being investigated. This is a pharmacokinetic study to be performed in children routinely treated with ketorolac for post surgical pain in line with local treatment protocols.
EUCTR2009-012512-41-GBHS Grampian
Active, not recruiting
Phase 1
Pharmacokinetic Study of Single and Multiple Dose of PKL-021 Administered Orally to Healthy Subjects/A submitted trial is conducted on healthy subjectsMedDRA version: 21.1Level: PTClassification code: 10036312Term: Post-traumatic epilepsy Class: 100000004852MedDRA version: 22.1Level: PTClassification code: 10076982Term: Post stroke epilepsy Class: 100000004852
CTIS2023-506633-30-00Pikralida Sp. z o.o.12